title: Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
abstract: BACKGROUND
  Non-alcoholic-steatohepatitis (NASH) leading to fibrosis, end-stage cirrhosis and hepatocellular carcinoma is an increasing health problem in the Western world. Thus, the need for new therapeutic approaches is increasing. IKK2 plays a key role in the development of NASH by mediating inflammation and insulin resistance.
  
  
  OBJECTIVE
  Here the beneficial effects of a pharmacological IKK2 inhibitor (AS602868) on initial stages of NASH progression were tested.
  
  
  METHODS
  Mice were fed with a high sucrose diet (HSD) and daily-administered AS602868 and vehicle. The impact of AS602868 on NASH progression was studied using biochemical, histological and molecular markers.
  
  
  RESULTS
  AS602868 treatment prevented HSD-induced weight gain and visceral fat accumulation. In adipose tissue, AS602868-treated mice exhibited a lower degree of infiltrated macrophages along with reduced proinflammatory cytokine production. Further analysis demonstrated that AS602868 treatment efficiently inhibited nuclear factor (NF)-kappaB activation in liver non-parenchymal cells and as a consequence attenuated the inflammatory response in the liver. Accordingly, in HSD/AS602868 mice, liver and adipose tissue adiponectin levels remained at levels comparable with those of control chow-fed mice, while they were decreased in HSD/vehicle animals. Additionally, AS602868 improved lipid beta-oxidation mediated by peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Systemic pharmacological IKK2 inhibition by AS602868 treatment efficiently prevented liver steatosis and inflammation, and improved antioxidant response. All this contributed to attenuation of NASH progression as evidenced by lower hepatocyte apoptosis and early stages of liver fibrosis.
  
  
  CONCLUSIONS
  The data demonstrate that AS602868-mediated IKK2 inhibition represents a new therapeutic approach to prevent dietary-induced NASH progression.
authors.affiliation: Department of Internal Medicine III, University Hospital, RWTH Aachen, Pauwelsstr. 30, D-52074 Aachen, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Beraza
authors.forename: Y
authors.initials: Y
authors.lastname: Malato
authors.forename: S
authors.initials: S
authors.lastname: Vander Borght
authors.forename: C
authors.initials: C
authors.lastname: Liedtke
authors.forename: H E
authors.initials: HE
authors.lastname: Wasmuth
authors.forename: M
authors.initials: M
authors.lastname: Dreano
authors.forename: R
authors.initials: R
authors.lastname: de Vos
authors.forename: T
authors.initials: T
authors.lastname: Roskams
authors.forename: C
authors.initials: C
authors.lastname: Trautwein
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004032:Diet; D005234:Fatty Liver / Q000188:drug therapy / Q000517:prevention & control*; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors*; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D009765:Obesity / Q000517:prevention & control; D047493:PPAR alpha / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D013395:Sucrose / Q000008:administration & dosage / Q000633:toxicity; D013549:Sweetening Agents / Q000008:administration & dosage / Q000633:toxicity; D014280:Triglycerides / Q000378:metabolism
chemical_list: C519899:AS602868; D000975:Antioxidants; D016328:NF-kappa B; D047493:PPAR alpha; D011743:Pyrimidines; D013549:Sweetening Agents; D014280:Triglycerides; D013395:Sucrose; D003094:Collagen; D051550:I-kappa B Kinase